Has Todd Bauer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,894,774 in general payments to Todd Bauer, MD across 3,427 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Todd Bauer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Todd Bauer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Todd Bauer, MD

Hematology & Oncology · Nashville, TNNPI 1336296136

Payments from drug & device makers

$10,894,774in general payments, 2019–2025

Across 3,427 payments — averaging $3179.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$4M
Incyte Corporation$1.1M
Novartis$1M
E.r. Squibb & Sons, L.L.C.$871K
Pfizer$690K
AbbVie$623K
plus $2.6M from 54 others

$58,190in research payments, 2019–2025

Across 47 payments — averaging $1238.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$47K
Novartis$10K
F. Hoffmann-la Roche AG$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	914	$3,981,130
Incyte Corporation	1,373	$1,106,195
Novartis	33	$1,032,349
E.r. Squibb & Sons, L.L.C.	37	$870,739
Pfizer(2 entities)	265	$690,313
AbbVie	122	$622,561
Eli Lilly	8	$596,596
GSK	132	$491,151
Genentech, Inc.	36	$318,278
Boehringer Ingelheim	13	$269,566
AstraZeneca	17	$223,113
Stemline Therapeutics Inc.	42	$173,864
Biontech SE	6	$103,571
Bayer	62	$98,524
Lilly USA, LLC	50	$69,038
Modernatx, Inc.	36	$52,469
Sanofi US Services Inc.	19	$44,003
Astrazeneca UK Limited	5	$28,472
Deciphera Pharmaceuticals Inc.	68	$25,037
Clovis Oncology, Inc.	13	$22,616
Amgen	5	$20,462
Boehringer Ingelheim Pharma GmbH & Co.kg	10	$15,872
Immunocore Limited	9	$8,442
Whitehall International Inc	1	$7,700
Foundation Medicine, Inc.	5	$4,480
Boehringer Ingelheim International GmbH	4	$3,040
Sanofi	6	$2,415
F. Hoffmann-la Roche AG	2	$2,130
Exelixis Inc.	5	$2,121
Bristol Myers Squibb	22	$1,506
Principia Biopharma Inc.	1	$1,200
Array Biopharma Inc	5	$852
Pfizer Pharma GmbH	2	$780
Tempus AI, Inc	1	$750
Regeneron Healthcare Solutions, Inc.	14	$532
Daiichi Sankyo Inc.	13	$374
TG Therapeutics, Inc.	3	$313
Genmab U.S., Inc.	2	$250
Gilead(2 entities)	6	$246
EMD Serono, Inc.	8	$218
Johnson & Johnson	3	$169
Eisai Inc.	7	$166
Sobi, Inc	2	$142
Genentech USA, Inc.	3	$142
ADC Therapeutics America, Inc.	1	$131
Pharmacyclics LLC, An Abbvie Company	4	$78
Taiho Oncology, Inc.	3	$61
AVEO Pharmaceuticals, Inc.	2	$61
Dendreon Pharmaceuticals LLC	2	$58
Rigel Pharmaceuticals, Inc.	3	$57
Pharmaessentia USA Corporation	2	$44
Astellas Pharma US Inc	2	$42
Mirati Therapeutics, Inc.	2	$42
Pharmacosmos Therapeutics Inc.	2	$39
Beigene USA, Inc.	2	$34
Ipsen Biopharmaceuticals, Inc	1	$33
Beone Medicines USA, Inc.	1	$26
Novocure Inc.	1	$23
Servier Pharmaceuticals LLC	1	$23
Kyowa Kirin, Inc.	1	$22

How this compares

$10,894,774 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$4,032,750

Medicare patients

559

Services billed

184,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Nashville

Erika HamiltonNashville$45.4M
Ian FlinnNashville$41.2M
Johanna BendellNashville$28.5M
Jesus BerdejaNashville$22.2M
Meredith McKeanNashville$16M
Krish PatelNashville$14.2M
Denise YardleyNashville$13.2M
Wade IamsNashville$8.9M
Benjamin GarmezyNashville$8.4M
Brian RiniNashville$8.1M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →